Eczema Edge: A Case-Based Expert Roundtable Discussion on IL-13 Inhibition for Moderate to Severe Atopic Dermatitis
Webinar/Online
Thursday, February 26, 2026 at 12:00pm ET - 1:00pm ET
Info
Topic
Engage with leading experts as they discuss strategies to identify patients who may benefit from biologic therapies targeting IL-13 based on the pathophysiology of AD. Gain practical insights into optimizing treatment decisions and deepen your knowledge of the clinical efficacy and safety of IL-13–targeted biologics for moderate to severe AD.
Credits Offered
This event offers
1.0 CME credit
to attendees.
Accreditation Info:
AAPA.
Additional Information
Agenda
- Introduction
- The Pleiotropic Role of IL-13 in Atopic Dermatitis
- Practical Evidence in IL-13 Inhibition for Moderate to Severe Atopic Dermatitis
- Evaluating Patient Candidacy for IL-13 Inhibitors
- Clinical Cases
- Key Clinical Takeaways, Final Q&A
Goal Statement
The goal of this educational activity is to improve learners’ knowledge, competence, and performance managing advanced therapy for patients with moderate to severe atopic dermatitis.
Target Audience
This activity is intended for dermatologists, allergists, pediatricians, primary care providers, pharmacists, nurse practitioners (NPs), and physician associates (PAs) who manage patients with moderate-to-severe atopic dermatitis.
Learning Objectives
Upon completion of this activity, participants should be able to:
-
Evaluate the therapeutic rationale for advanced therapies targeting IL-13 based on the pathophysiology of AD
-
Assess the clinical profile, safety, and efficacy of advanced therapies targeting IL-13 in moderate to severe AD
-
Recognize patient candidates for advanced biologic therapies targeting IL-13 in moderate to severe AD
Speakers
Adult Nurse Practitioner at VA Portland Health Care System
Ms. Lakshi Aldredge is an Adult Nurse Practitioner who practices at the VA Portland Healthcare System in the Dermatology Service and is also the Director for the Primary Care NP Residency Program. She obtained her Master of Science in Nursing Degree from the University of Portland in 1998 as well as national certification as an Adult Nurse Practitioner that same year. She obtained her Dermatology Nurse Practitioner Certification in 2018. She is Past Chair of the Nurse Practitioner Society of the Dermatology Nurses’ Association (DNA), Past President of the DNA and past Co-chair of the Dermatology Specialty Practice Group of the American Academy of Nurse Practitioners. She currently serves as the President of the Society of Dermatology Nurse Practitioners. She is a member of the National Psoriasis Foundation Emeritus Medical Advisory Board and served on the Editorial Board for the Journal of the Dermatology Nurses’ Association, and is Associate Editor for Journal of Psoriasis and Psoriatic Arthritis. She has a special interest in psoriasis, as well as in educating health care providers about the role of NPs in the field of dermatology. Ms. Aldredge has published numerous articles on the management of patients with psoriatic disease. She received the VA’s Nursing Excellence Award in 2008 and the President’s Award from the DNA in 2015. She also received the 2016-17 Outstanding Allied Health Award from the National Psoriasis Foundation. In March 2021, she was selected as a Fellow of the American Association of Nurse Practitioners.
Professor of Clinical Dermatology
Weill Cornell Medicine
New York, New York
Professor of Pediatrics and Dermatology
Interim Division Chief, Allergy, Immunology and Rheumatology
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin